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ABSTRACT
Introduction Several European studies suggest that
some patients with appendicitis can be treated safely
with antibiotics. A portion of patients eventually undergo
appendectomy within a year, with 10%–15% failing
to respond in the initial period and a similar additional
proportion with suspected recurrent episodes requiring
appendectomy. Nearly all patients with appendicitis
in the USA are still treated with surgery. A rigorous
comparative effectiveness trial in the USA that is
sufficiently large and pragmatic to incorporate usual
variations in care and measures the patient experience
is needed to determine whether antibiotics are as good
as appendectomy.
Objectives The Comparing Outcomes of Antibiotic Drugs
and Appendectomy (CODA) trial for acute appendicitis aims
to determine whether the antibiotic treatment strategy is
non-inferior to appendectomy.
Methods/Analysis CODA is a randomised, pragmatic
non-inferiority trial that aims to recruit 1552 Englishspeaking and Spanish-speaking adults with imagingconfirmed appendicitis. Participants are randomised to
appendectomy or 10 days of antibiotics (including an
option for complete outpatient therapy). A total of 500
patients who decline randomisation but consent to followup will be included in a parallel observational cohort.
The primary analytic outcome is quality of life (measured
by the EuroQol five dimension index) at 4 weeks.
Clinical adverse events, rate of eventual appendectomy,
decisional regret, return to work/school, work productivity
and healthcare utilisation will be compared. Planned
exploratory analyses will identify subpopulations that may
have a differential risk of eventual appendectomy in the
antibiotic treatment arm.
Ethics and dissemination This trial was approved by
the University of Washington’s Human Subjects Division.
Results from this trial will be presented in international
conferences and published in peer-reviewed journals.
Trial registration number NCT02800785.

Strengths and limitations of this study
►► This trial will evaluate the comparative effectiveness

of antibiotics and appendectomy for appendicitis
based on a comprehensive assessment of impact,
including the full range of clinical outcomes and
patient-reported outcomes that matter most to
patients.
►► This pragmatic trial was designed to account for the
diverse aspects of the population, practice settings
and practices in the USA.
►► This study builds on the successful experience of
clinicians to manage patients with potentially serious
infections as outpatients using risk stratification and
long-acting parenteral antibiotics.

Introduction
Acute appendicitis is the most common reason
for an urgent abdominal operation, with a
lifetime incidence of 7%–15%.1 Each year,
nearly 300 000 Americans are hospitalised
for appendicitis at a cost of US$7.8 billion.2 3
While appendectomy has been the treatment
of choice for 120 years, the successful use of
antibiotics was reported both in a series of
over 500 patients treated with streptomycin
in the 1950s and later in submariners who
did not have access to surgical teams.4 5 As
anaesthesia and surgical safety improved
throughout the 20th century, the antibiotics
treatment strategy was relegated to patients
with disease severe enough (eg, phlegmon at
the cecum, abscess) that surgeons felt there
was a higher risk for surgical complications or
the need for a more extensive procedure.
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Based on these successes with an antibiotic strategy,
in the 1990s, European investigators began challenging
the notion that surgery was the best approach to treat
acute ‘uncomplicated’ appendicitis with a series of
randomised trials comparing antibiotics and appendectomy.4 6–10 A recent meta-analysis of six randomised trials
including 1724 randomised adult patients concluded
that there was a high level of efficacy (91% success in
the short term with 71% appendectomy-free by 1 year),
less pain and a quicker return to work in the antibiotic
arm.11 The largest, most rigorous and recent trial found a
lower rate of postinterventional complications (reported
as clinical wound infections, incisional hernia, abdominal pain or obstructive symptoms) in the antibiotics
group requiring intervention when compared with those
having open surgical procedures.12 However, in addition
to the potential for recurrence of appendicitis, a small
proportion of patients treated with antibiotics likely had
a neoplasm that would have been incidentally identified
had they undergone appendectomy. A recent meta-analysis reported incidental appendiceal neoplasm in 5 of 843
(0.59%) patients undergoing surgery.11 The meta-analysis overall concluded that laparoscopic appendectomy
remains the usual treatment for appendicitis and there
is a ‘poor evidence base overall with numerous areas of
bias’, limiting the use of the data for decision making.
The limitations of the existing data regarding antibiotics as a primary treatment for acute appendicitis have
been systematically reviewed.13 Most studies had small
sample sizes; several did not have standardised imaging
for diagnosing appendicitis, leading to inclusion of
patients who likely had ‘complicated’ appendicitis and
patients without appendicitis; inexact and subjective
outcome definitions and operation/reoperation criteria
were used; there were limited or no laparoscopic options
for surgery and, in some cases, inadequate antibiotic regimens allowed; and most had short follow-up (no studies
reported following patients beyond 1 year).13 While some
studies evaluated outcomes including general pain scores
and use of narcotic pain medication, no study used a validated patient-reported outcome (PRO) tool to measure
the patient’s experience in a standardised fashion. Other
important outcomes to patients such as impact on work
and school productivity, lingering symptoms, decisional
regret and healthcare burden (such as emergency room
care or future imaging) were not included in prior
studies. Furthermore, prior studies regimented care in
ways that are not consistent with care in the USA, such as
requiring several days of inhospital convalescence. These
limitations may explain the infrequent use of antibiotics
as the primary treatment for appendicitis in the USA.14
In addition to the need to address these limitations,
there are additional, unresolved questions that make a
larger, more definitive study of this treatment question
important. First, there may be important subgroups of
people with acute appendicitis who experience the treatment differentially. These might include older patients,
who are at higher risk for surgical complications, those
2

with possible appendiceal perforation detected on
imaging or those with an appendicolith. The association
between appendicolith and worse outcomes with antibiotics is unclear. Appendicoliths are found in up to 20% of
appendicitis cases; a similar proportion is also described
in autopsy studies of normal appendices.15 In several
paediatric studies and at least one adult study, appendicolith seemed to be associated with eventual appendectomy; however, since many trials did not include
standardised imaging or criteria for requiring appendectomy following antibiotic therapy for appendicitis, it
is unclear if the presence of an appendicolith actually
confers a greater risk.16 17 There is currently no standard
definition of ‘complicated’ disease. In the USA, usual
care for appendiceal abscess or phlegmon (inflammation
so significant that surgeons are concerned for associated
surgical morbidity) is antibiotics with consideration for
interval appendectomy. Optimal treatment strategies for
preoperative radiographic findings of appendiceal perforation are an area of controversy. The use of radiologic
imaging to accurately determine perforation is limited;
in prior randomised trials, patients with perforation were
likely to have been inadvertently included due to a lack
of imaging.18 Finally, the European studies mandated the
use of inpatient antibiotics at a time when there was a
growing use of outpatient antibiotic regimens for similar
conditions, such as acute diverticulitis.19–21 A recently
completed, pilot randomised trial in the USA found that
14 of 15 adults randomised to antibiotics could successfully be discharged from the emergency department (ED)
and receive all their care as outpatients, resolving their
symptoms of acute appendicitis.22 One of the remaining
questions is whether this total outpatient approach to
antibiotics would be as good as appendectomy in usual
practice.
Given these evidence gaps it remains to be determined
if, from the patient’s perspective, the antibiotic treatment
approach is similar, definitively not worse, and perhaps
even superior than the standard treatment of appendectomy. The Comparing Outcomes of Antibiotic Drugs and
Appendectomy (CODA) trial was designed to address
this question and inform decision-making, focusing on
commonly used surgical strategies and a range of antibiotic strategies, including total outpatient therapy, across
a broad range of practice environments and a heterogeneous group of patients. These questions provide strong
motivation for a pragmatic trial of antibiotics for acute
appendicitis.
Trial design
Stakeholder input in design, informed consent and protocol
A central feature of the CODA trial is its engagement
of stakeholders in study conception, design, and implementation of the trial.23 The Stakeholder Coordinating
Center (SCC), established as a formal core within the
study infrastructure, facilitates all engagement activities. The SCC engages representatives from the patient
Davidson GH, et al. BMJ Open 2017;7:e016117. doi:10.1136/bmjopen-2017-016117
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population of interest (those at risk for or who have had
appendicitis), clinicians who are involved in appendicitis
treatment (including emergency physicians, nurses and
surgeons), leaders of professional societies (American
College of Surgeons and American College of Emergency
Physicians), representatives of Accountable Care Organizations, policy-makers, insurers and payers, researchers
and leaders from large self-insured employers. Specific
areas of protocol development informed by SCC included
selecting primary and secondary outcomes. In addition
to the routine clinical metrics that are assessed in any
study of appendicitis treatment, other outcome measures
important to patients (anxiety, quality of life (QoL), time
away from work, out-of-pocket expenses) and employers
(time away from work and productivity at work) were
included. Stakeholder input was particularly helpful
in determining the primary analytic outcome, helping
weigh the prior evidence showing no difference in rates
of complications with an outcome metric that would ‘sum
up’ the impact of both treatments on the care experience
of patients.
Because appendectomy was considered the standard
and nearly universal therapy in the USA, advisors recommended a study that considered the non-inferiority of
the antibiotics-first strategy. As one advisor said, ‘the
burden of proof is on the antibiotics treatment approach
to demonstrate that it is as good as appendectomy’ (or
not inferior by more than a small margin). Advisors also
favoured a non-inferiority framework because the larger
size required for this design would also allow for multiple
planned subgroup analyses for patient groups of interest
and the possibility that superiority of the PRO measure
might be demonstrated. Lastly, advisors suggested a
parallel observational cohort to assess for potential selection bias for patients who declined randomisation.
Patient advisors with an experience of incidentally
identified neoplasm at the time of appendectomy helped
modify the inclusion criteria (excluding all patients with
suggestion of mass of the appendix on imaging) and
consent form (adding language to make sure that patients
were informed about this risk, estimated to be 0.6%) and
directed a change in the protocol (those with lingering
symptoms in the antibiotics group would be directed to
follow-up visits and usual care diagnostic evaluations to
rule out a neoplasm).
Study aims and hypothesis
The aims of the study are to compare PROs and clinical
outcomes in patients randomised to antibiotics or appendectomy. We hypothesise that antibiotics are non-inferior
to appendectomy for PROs and that there are subgroups
with better outcomes (clinical and patient reported)
with either treatment. A second set of aims is to perform
subpopulation analyses for patients with appendicolith
and imaging correlates that may indicate higher risk of
requiring appendectomy following initiation of antibiotic therapy, advanced age, sex, comorbid conditions and
insurance status.
Davidson GH, et al. BMJ Open 2017;7:e016117. doi:10.1136/bmjopen-2017-016117

Study population
The study population includes consecutively presenting
English-speaking or Spanish-speaking adults (age ≥18
years) with clinically suspected and imaging-confirmed
acute appendicitis who present at study site hospital EDs
in several states.
Exclusion criteria
Inability to participate in follow-up (ie, incarcerated,
travel without access to phone, email)
►► Contraindication to one of the study treatment arms:
–– Septic shock (evidence of severe sepsis or septic
shock includes new presumed sepsis-related
organ dysfunction, elevated lactate and/or fluid
unresponsive hypotension)
–– Phlegmon for which surgery would not be
recommended or diffuse peritonitis for which
antibiotics alone would not be recommended
–– Imaging findings of walled off abscess and/or free
air
–– Appendiceal soft-tissue mass concerning for
malignancy
►► Other conditions precluding study involvement:
–– Uncompensated liver failure
–– Inflammatory bowel disease requiring active
medical treatment (eg, Crohn’s, ulcerative colitis)
–– Pregnancy or expectation of becoming pregnant in
the 30 days following baseline/screening.
–– Surgical implant (eg, left ventricular assist device,
peritoneal dialysis)
–– Malignancy
requiring
active
treatment
(eg, chemotherapy)
–– Immunodeficiency (eg, AIDS)
–– Another infection currently treated with systemic
antibiotics
–– Concurrent illness that would otherwise mandate
inpatient hospitalisation
–– Severe allergy or reaction to all proposed antibiotics
–– Abdominal or pelvic surgery in the past 30 days.
Of note, patients with radiologic diagnosis of appendicolith and/or imaging concerning for appendiceal
perforation or phlegmon are included if they do not meet
the above exclusion criteria and are otherwise eligible.
►►

Recruitment
All patients presenting to the ED with concern for
appendicitis are screened by study coordinators (7 days
a week, at least 18 hours per day) based on alerts from
clinicians, staff and screening of ED logs. Patients are
identified as potential study candidates based on eligibility criteria collected as part of standard care, including
confirmatory diagnostic imaging (CT, ultrasound and/
or MRI). A research coordinator and a representative
from the clinical team confirm the patient’s eligibility
for the study. A research team member approaches
all eligible patients and invites them to view a less than
10 min standardised informed decision-making video
providing standard information about appendicitis and
3
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Table 1 Participant assessment schedule
Follow-up time point
First 4 weeks
Baseline

1

Participant point of
contact
Contact information

Site RT

Site RT

x

x

x

x

x

x

x

x

x

EQ-5D42

x

x

x

x

x

x

x

x

10-PROMIS Global Health x
short form43

x

x

x

x

x

x

x†

x

x

x

x

x

PROMIS Pain Intensity

x

Symptom onset

x

x

2

Month

Item

4

3

6

9

12

18

24

Survey centre
x

x

Additional demographics* x
Treatment satisfaction/
expectation

x

Gastrointestinal Quality of
Life Index44
Healthcare utilisation

x

x

x

x

x

x

x

x

x

Signs and symptoms of
appendicitis

x

x

x

x

x

x

x

x

x

Adverse events

x

x

x

x

x

x

x

x

x

Decision Regret Scale45
Major life changes

x

x

x

x

x

x

Work Productivity Index

x

x

x

x

Return to work
information

x

x

x

x†

Medication use
Treatment strategy
change

x
x

x
x

x
x

x†

x
x

x

x

*Includes the following topics: demographics and gender identity, caregiver role, instrumental support, employment/student status, income,
pain catastrophising, health literacy, social support, confidence in treatment success and trust in healthcare.
†Only asked if the 1-month results have not normalised.
EQ-5D, EuroQol five dimension; PROMIS, patient-reported outcomes measurement information system; RT, research team.

the different treatment options (offered in English and
Spanish versions, https://www.youtube.com/playlist?list=
PLQUQ6jdR0MPaq-a8CvSdhVwnuYzNKF9tu).
Participants who decline randomisation are asked
to participate in the observational cohort (with similar
baseline and follow-up measures as participants in the
randomised controlled trial). All patients are asked for
permission to be followed through passive electronic
medical record (EMR) review.
Participant follow-up assessment
Participants are contacted 24–48 hours after discharge
by a member of the research team to answer any questions about the study and review the survey protocol
(see table 1). Participants are then contacted by phone by
site research coordinators 1 and 2 weeks after enrolment
for study assessments. Data collected through the 2-week
assessment are entered by site research coordinators into
a REDCap database, which is managed by the University
of Washington (UW) data coordinating centre (DCC).24
4

Starting with the week 4 assessment, corresponding
to our primary endpoint assessment, participants are
contacted by phone, mail or email by the UW Survey
Center to complete the remaining study assessments (at
3, 6, 9, 12, 18 and 24 month surveys). The UW Survey
Center uses the DatStat survey platform (DatStat, Seattle,
Washington, USA) to create individualised outreach plans
that optimise survey completion rates. Outreach methods
are modified to accommodate a participant’s preferred
mode of contact (email, mail, phone) as well as time of
day for contact (if by phone). If a participant requests to
speak with a medical provider or has concerning medical
symptoms reported to the research team, the clinical
team via the surgical site lead is contacted to call the
participant for further follow-up.
The DCC performs early quality assurance checks by
running REDCap data quality reports. These reports identify missing values for required fields, incorrect data type,
range checks, outliers, hidden fields that contain values
Davidson GH, et al. BMJ Open 2017;7:e016117. doi:10.1136/bmjopen-2017-016117
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and multiple-choice fields with invalid values. Values that
need to be corrected are brought to the attention of the
research staff at that site.
Study arms
Antibiotics therapy arm
Patients in the antibiotics treatment arm receive a
minimum of 24 hours of treatment using an intravenous antibiotic formulation (administered in q8, q12
or q24 hour regimens) followed by oral antibiotics for
a total of a 10-day antibiotic course. Patients are offered
a treatment regimen of antibiotics based on guidelines
published jointly by the Surgical Infection Society (SIS)
and the Infectious Disease Society of America (IDSA) for
intravenous antibiotics25 and oral antibiotics based on in
vitro activity against aerobic and anaerobic Gram-negative bacteria, practical experience with oral antibiotic
regimens used to treat diverticulitis and IDSA/SIS guidelines. The first dose of antibiotics is given in the ED at the
time of diagnosis of appendicitis, and a total outpatient
regimen of antibiotics is an option for patients meeting
ED discharge criteria. Antibiotics are procured from the
pharmacy by the patient as per usual clinical care.
Appendectomy is recommended only if there is
development of diffuse peritonitis, development of
septic shock26 and/or worsening signs and symptoms of
appendicitis after 48 hours. The decision to perform an
appendectomy in participants randomised to antibiotics
is made by the treating surgeon after consultation with
the study clinical research lead to confirm that the above
criteria have been satisfied.
Standard discharge criteria are applied to those treated
in the ED and those who are admitted, and the criteria
include tolerance of liquids, adequate pain control
and improving clinical condition. All participants are
contacted at 24–48 hours by the research coordinator to
review the study protocol for follow-up assessments.
Follow-up with the clinical team is per usual care at each
institution. Participants in the antibiotics arm who return
to any of the study sites during the follow-up period with
recurrent appendicitis are not rerandomised but are
offered the choice of either appendectomy or another
antibiotic course, if treating surgeon agrees that their
recurrence can be treated with either option.
Appendectomy therapy arm
All patients randomised to appendectomy receive preoperative antibiotics per hospital standards for surgical infection prevention protocols. Appendectomy is performed
by an open or laparoscopic approach, depending on
patient and surgeon preference.
Blinding and randomisation
This is an unblinded study as patients will know if they
were randomised to appendectomy or antibiotics. A separate DCC at UW generates and maintains randomisation
lists for each practice site. Using block randomisation
optimises the chances of equal numbers of subjects being
Davidson GH, et al. BMJ Open 2017;7:e016117. doi:10.1136/bmjopen-2017-016117

randomised to each treatment arm, and that treatment
is balanced at periodic enrolment intervals. Randomisation is further stratified by the presence of appendicolith.
All other subgroups of interest will be sufficiently large
such that the risk of a meaningful imbalance in treatment
groups by chance is unlikely. A web-based portal provides
the randomised treatment assignment.
Outcomes and measures
The primary outcome for the CODA trial is the EuroQol
five dimension (EQ-5D) index reported 4 weeks after
randomisation. In addition, important clinical outcomes
include major complications and resolution of symptoms
by 4 weeks; eventual appendectomy (due to failure in clinical improvement, progression of disease severity or due
to recurrent appendicitis), pain, narcotic use, recurrent
episodes of appendicitis, ED visits for abdominal pain/
repeat imaging, need for more complicated surgical
procedure including laparoscopic converted to open
appendectomy and ileocecectomy, rates of perforation
and rates of future small bowel obstructions and hernia
development are collected and will be reported through
2 years. Complications in both treatment groups are
tracked and adjudicated by an independent safety monitor
to determine their relation to the disease and treatment.
Secondary PROs include a measure of decisional regret,
anxiety, additional QoL measures (PROMIS-Global,
Gastrointestinal Quality of Life Index), days missed from
work or school, time in healthcare, measures of caregiver
burden and out-of-pocket expenses.
Sample size
The sample size was calculated based on the difference in
EQ-5D between the two treatment interventions (table 2).
The EQ-5D QoL index ranges from 0 (worst QoL) to
1 (highest QoL), where anchor-based methods have
shown that the minimally clinically important difference
ranges 5%–10%.27 On the basis of data from a prior
study of appendectomy with EQ-5D scores at 12 weeks,28
we estimate that the average EQ-5D for the participants
randomised to appendectomy will be 0.90 with an SD of
0.12. To assess QoL differences between interventions, a
total of 1552 patients will be enrolled, assuming a 90%
follow-up at 4 weeks. This will give the study very high
power (>99%) to rule out an EQ-5D difference between

Table 2 Statistical power to declare non-inferiority on
patient-reported quality of life, overall and by subgroup
(non-inferiority margin, M=−5%, one-sided alpha=0.025)
Treatment
difference,
Δ (%)

Overall (%)

Subgroups (%)

n=1552

n=250

n=400

n=500

−3
−2

82.6
99.4

–
–

–
57.1

–
67.9

−1
0

100
100

62.4
83.0

83.8
96.4

91.4
98.8
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hospital days, number of days using antibiotics beyond
the initial treatment, clinic visits and caregiver/patient
‘time in healthcare’) will also be compared between
intention-to-treat (ITT) groups using regression models
appropriate to each endpoint (eg, linear, logistic, Poisson
or Cox proportional hazards regression models), along
with a similar non-inferiority framework.
Figure 1 Example study conclusions in the Comparing
Outcomes of Antibiotic Drugs and Appendectomy trial.
There are four possible study conclusions. (A) The observed
treatment effect (black circle) of antibiotics is almost zero
and the 97.5% one-sided CI (arrow) does not overlap the
non-inferiority margin of −5%, indicating that antibiotics is
a non-interior strategy. (B) The observed treatment effect
of antibiotics is more than 2.5% better than appendectomy
and the CI does not include 0, indicating that antibiotics are
superior. (C) The observed treatment effect of antibiotics
is 2.5% worse than appendectomy but the CI includes
−5%, so non-inferiority cannot be claims. (D) The observed
treatment effect of antibiotics is more than 5% worse than
appendectomy, indicating that antibiotics are inferior.

groups as small as 5% (if treatment differences of 0%–2%
are observed) and 80% power if a treatment difference of
3% is observed.22
On the basis of pilot data and stakeholder engagement, we estimate a randomisation rate of 30% of all
potential patients. Based on current appendectomy
volume at the hospitals participating in the trial, recruitment is planned for 3 years with potential for extension
through 4 years.
Statistical analysis
We will assess the EQ-5D at 4 weeks, using a linear regression model that adjusts for an indicator of randomised
treatment group assignment and for all factors used to
stratify randomisation (ie, recruitment site, presence of
appendicolith). As recommended by the US Food and
Drug Administration guidelines on clinical trial design,
the estimated treatment effect and 97.5% one-sided
CI will be compared with the non-inferiority margin
(M=−5%).29–32 We will conclude that antibiotics are non-inferior to appendectomy if the entire 97.5% one-sided CI
is greater than M, as in example scenario A (figure 1).
This is equivalent to a one-sided (alpha=0.025) test of the
null hypothesis H0: Δ<−5%, for which Δ represents the
difference in mean EQ-5D at 4 weeks comparing antibiotics-first to appendectomy-first treatment assignment. If
the null hypothesis of H0: Δ<−5% is rejected at the final
evaluation, then we will conduct a test of superiority to
determine the level of statistical evidence supporting
an alternative hypothesis HA: Δ>0% (ie, scenario B of
figure 1).
Important clinical endpoints (30-day major complications, days until resolution of symptoms, rates of perforated appendicitis, extent of operation and surgical
complications, complications associated with antibiotics,
6

Secondary analyses
We aim to include a heterogeneous population of
patients and healthcare settings and plan to explore
differences in treatment outcomes across subgroups of
interest, including those with appendicolith, people with
specific imaging findings including possible appendiceal perforation, those in different age groups (18–64 or
≥65) and sex and those whose outcomes may vary due to
differences in work and insurance status, comorbidities
or social support. We will evaluate difference in treatment
effectiveness based on modality of receipt of antibiotics
(all outpatient vs inpatient/outpatient). We will separately assess treatment effect heterogeneity by adding to
the primary outcome model an interaction term between
the categorical subgroup variable of interest and the indicator of treatment. We will use a global likelihood ratio
test to examine if the treatment effect differs between key
subgroups of interest.
An ITT approach will be applied in the primary analysis. We will conduct a secondary as-treated analysis of the
primary outcome measure that appropriately accounts for
patient-level or provider-level characteristics found to be
differentially represented among patients who start in the
antibiotics arm and who undergo appendectomy before
24 hours of treatment or patients who are randomised to
appendectomy but refuse the procedure and continue
on antibiotics. We will consider a two-stage approach for
this as-treated analysis: (1) to identify subgroups that are
likely to require appendectomy and therefore should
not be considered good candidates for treatment with
antibiotics as primary treatment strategy and (2) to estimate the complier average causal effect, which seeks to
compare the outcomes of patients treated successfully
in the antibiotic treatment arm (ie, did not ultimately
have surgery) with patients randomised to the appendectomy arm who are similar in their expected compliance
to assigned treatment.33–35 We will use a maximum-likelihood mixture modelling approach to identify the optimal
comparison group from the control arm for observed
compliers in the intervention arm. Secondary analyses
of the primary outcome measures will include examining the entire trajectory of EQ-5D QoL measurements
for each patient using linear mixed-effects models for
longitudinal data.36 Finally, a composite outcome metric
(symptom resolution without complication) was used in
the recently completed pilot trial and will be included
as an exploratory measure.22 Because the composite
outcome includes only clinical domains, and is relevant
to both treatment groups, this may be a helpful measure
for clinicians considering the two treatments.
Davidson GH, et al. BMJ Open 2017;7:e016117. doi:10.1136/bmjopen-2017-016117
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Data safety and monitoring
Event reporting
Death, life-threatening events and rehospitalisation (other
than for treatment of appendicitis) are classified as serious
adverse events (SAEs). Morbidity events (using modified
definitions from the National Surgical Quality Improvement Program (NSQIP) to accommodate non-operative
care) are considered adverse events (AEs). AEs, SAEs
and appendectomy after starting antibiotic treatment are
identified through three approaches; EMR review, patient
surveys and ad hoc reporting by any research or care team
member. All SAEs are adjudicated by an independent
safety monitor. SAEs and AEs are reviewed by the data and
safety monitoring board (DSMB) biannually (with the
exception of death, which is reported to the DSMB within
24 hours). An independent DSMB reviews the accruing
data to (1) ensure that study conduct, enrolment and
patient follow-up is adequate; (2) ensure that there are
no serious safety concerns and (3) assess evidence related
to patient-reported QoL. The analysis of accruing data is
completed by the DCC, and interim analysis is presented
to the DSMB with the primary goal of monitoring safety
outcomes by randomisation group. Interim monitoring
for SAE and AE will focus on the first 4 weeks of follow-up.
The DSMB will conduct interim analyses at 12, 24 and 36
months.
The CODA trial does not include a stopping rule if
non-inferiority is met before complete accrual or if it is
determined that non-inferiority cannot be demonstrated
in interim analyses. We are not employing a stopping
rule because there are important secondary outcomes
(eg, rate of eventual appendectomy, complications,
subgroup analysis) and understudied subgroups that
require full enrolment.
Discussion
Prior trials randomising patients with appendicitis to antibiotics compared with appendectomy focused on disease
cure, with the primary outcome being the rate of appendectomy among antibiotic-treated participants. Previous
studies of more than 800 participants randomised to
antibiotics suggested that the treatment did not increase
the rate of complications and offered as high as a 75%
chance of avoiding appendectomy within a year.6–9 12 37
What remains to be evaluated is the comparative effectiveness of the two candidate treatments based on a comprehensive assessment of impact, including the full range of
clinical outcomes and PROs that matter most to patients.
CODA’s pragmatic design aims to evaluate antibiotics in a
heterogeneous population and practice settings in a large
randomised trial, with a parallel observational cohort to
assess selection bias. One of the greatest novelties of the
CODA trial is its patient centredness, demonstrated both
by the engagement of patients and other stakeholders as
partners in selecting the topic, designing the proposal,
developing the protocol and overseeing operations and in
the selection of a QoL endpoint for the primary analysis.
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CODA was designed to directly inform patient and
clinician decision making in the community, and several
pragmatic features were added to make sure it accounted
for the diverse aspects of the population, practice settings
and practices in the USA. As a pragmatic trial, CODA
has limited exclusion criteria and incorporates the many
ways clinical care is delivered across sites of practice. The
protocol allows patients in either study arm to leave the
healthcare setting as soon as standard discharge criteria
are met, including the possibility of completely outpatient
care. CODA takes place in diverse study sites (academic,
private, public, community and county hospitals) with
patients from a wide range of demographic and socioeconomic characteristics, including both Spanish and
English speakers. This enhances the generalisability of the
findings, but may compromise study fidelity if patients in
any one group have differential treatment preferences or
prove more difficult to contact for follow-up. A downside
to this approach is that, by including nearly all patients
with appendicitis (including those with appendicolith
and radiographic findings of perforation who may be at
higher risk for requiring an appendectomy) and those
undergoing total outpatient antibiotics (which clinicians
have less experience with), there is a risk of subgroups
with very different outcomes from the broader population and a skewing of the average study results. Using
Thorpe’s PRagmatic-Explanatory Continuum Indicator
Summary rubric for pragmatic trials, the proposed study
is considered highly pragmatic, intended to improve the
generalisation and precision of decision-making beyond
the prior randomised studies.38
The results from the European trials of antibiotics
have not significantly changed care delivery in the USA
and have been met with resistance, in part due to the
evidence gaps cited earlier and concern about the fate of
patients with recurrent disease.39 American patients may
also have different expectations and resources that influence perception of treatment success and satisfaction
with treatments. One particular protocol component of
the European trials that may make them less applicable
to the US experience is that prior studies all required an
inhospital convalescence for a fixed period of time for
both treatment arms that is double the length of stay that
the average US patient experiences. CODA builds on the
successful experience of emergency medicine clinicians
to manage patients with potentially serious infections
as outpatients using risk stratification and long-acting
parenteral antibiotics (eg, diverticulitis), and its effectiveness will be tested in different practice settings and populations. This novel treatment alternative offers avoidance
of hospital admission and may substantially reduce costs
compared with surgical treatment,
Stakeholder input is a key component of the emerging
field of patient-centred outcomes research. However,
including several types of stakeholders (patients, physicians, payers and purchasers) does not always result
in consensus. The selection of an appropriate analytic
outcome for the trial was an example. While prior
7
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studies focused on clinical outcome (eg, rates of appendectomy and surgical complications), patient advisors
recognised that these outcome measures are specific
to only one treatment arm (and to people treated with
antibiotics who proceed to appendectomy) and that
standardised measurements of QoL would be applicable to both and had yet to be rigorously assessed. The
EQ-5D has been used in prior studies of appendectomy,
but never in comparisons of these two treatments.28
Using the EQ-5D as a primary outcome measure was
highly relevant to many, but not all, patients. There is
a possibility that the primary analytic outcome analysis
(non-inferiority of the EQ-5D) could be positive, but
other outcome domains might not be aligned. For this
reason, multiple secondary analyses and exploratory
endpoints have been selected a priori. Evidence in the
field of decision-making suggests that patients want
information on multiple domains, but we recognise
that multiple outcome domains may also add confusion to interpretation of results and implementation in
future practice.
As in all trials, patients are not required to stay in the
treatment arms they are assigned to (non-adherence
or crossover); for example, select patients in the antibiotics arm might not be willing to receive 24 hours of
antibiotics and opt for an appendectomy despite not
meeting clinical trial protocol recommendations or
patients randomised to appendectomy might refuse
surgery. While the main analytic approach is an ITT
framework, careful as-treated and secondary data analyses may be helpful in accounting for such non-adherence/crossover.40 Detry and Lewis recommend both an
ITT and a careful as-treated analysis to address crossovers in non-inferiority trials where non-adherence or
crossover is present.41 A simple as-treated analysis is
problematic because of potential differences in demographic or clinical characteristics that introduce bias in
as-treated group comparisons. Our analytic approach
proposed involves a two-stage as-treated analysis and
potentially will yield conclusions that differ from ITT
analysis. However, the ITT results will be considered the
primary analysis and are robustly valid since they only
depend on randomisation and do not depend on model
assumptions required for observational comparisons.41
CODA began recruitment in the summer/fall of 2016
with eight hospitals in Washington and California with
additional hospitals across the United States planned
to begin recruitment in 2017. It is possible that not
all clinical sites will continue to contribute patients
throughout the entire recruitment period (projected to
be 3–4 years). Substudies and ancillary studies are being
proposed to focus on biomarkers, economic analysis,
longer-term results and other predictors of outcome.
In conclusion, the CODA trial was designed to
address critical knowledge gaps related to the treatment of appendicitis with antibiotics compared with
appendectomy. CODA’s stakeholder-informed design
and operations, pragmatic design and inclusion of an
8

innovative approach to outpatient antibiotics aim to
inform choices in care for this common condition,
and planned subgroup analyses allow for improved
decision making.
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